Commercial antibodies used were as follows: anti-FLAG (Sigma), anti-CDYL (Sigma, HPA035578; for Western blotting), anti-CDYL (Abcam, ab5188), anti-BrdU (Abcam, ab6326), anti-RPA1 (ABclonal, A0990), anti-RAD51 (ABclonal, A6268), anti-WRN (ABclonal, A6855), anti-DNA2L (Abcam, ab2179), anti-BLM (Abcam, ab96488), anti-MRE11 (Cell Signaling Technology, 4847), anti-NBS1 (Cell Signaling Technology, 14956), anti-RAD50 (Cell Signaling Technology, 3427), anti-Myc, anti-hemagglutinin (HA), anti–β-actin (MBL), anti-PanKac (PTM, 101), anti-PanKcr (PTM, 502; for Western blotting), and anti-PanKcr–conjugated agarose beads (PTM, 503; for immunoprecipitation). A CDYL antibody that we generated previously (peptide antigen: KQKESTLTRTNRTSPNN; B&M) was used for immunoprecipitation. The polyclonal antibodies against RPA1 K88cr, RPA1 K379cr, and RPA1 K595cr were generated by immunizing rabbits with two synthetic crotonyl peptides corresponding to residues surrounding K88, K379, and K595 of RPA1, respectively. HU, CPT, and VP16 were from Sigma. Streptavidin agarose resins were from Thermo Fisher Scientific. Protein A/G and Sepharose CL-4B beads were from GE Healthcare Biosciences, and protease inhibitor mixture cocktail was from Roche Applied Science.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.